 Home > Active Ingredient News > Antitumor Therapy > Major milestone: The third-generation ALK inhibitor lorlatinib, an innovative lung cancer drug, was approved in China

Major milestone: The third-generation ALK inhibitor lorlatinib, an innovative lung cancer drug, was approved in China

 Last Update: 2022-05-22
 Source: Internet
 Author: User

Tags

biochemistry study

jujube health benefits

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 29 , 2022 , Pfizer announced that the world's first third-generation ALK inhibitor Borrena® ( Lorbrena® ^, generic name: Lorlatinib Tablets ⁾ was approved by the State Drug Administration for single drug use for the treatment of patients with anaplastic lymphoma kinase ( ALK )-positive locally advanced or metastatic non-small cell lung cancer ( NSCLC ) .

On April 29 , 2022 , Pfizer announced that the world's first third-generation ALK inhibitor Lorbrena ® ⁽ Lorbrena ® ^,generic name: ^LorlatinibTablets/Lorlatinib Tablets ) was approved by the National Medical Products Administration ^{.

" Today we have reached another major milestone in the history of the treatment of ALK -positive advanced NSCLC ! With the approval of this ground- ^{breaking innovative therapy,}^Borrena® , patients will live longer and with higher quality, which is what Pfizer is doing .

In China, lung cancer ranks first in morbidity and mortality, and the disease burden is increasing.

" Recently published clinical study data from the American Association for Cancer Research ( AACR ) show that the progression-free survival ( PFS ^{) of}^Briner® in the first-line treatment of ALK -positive NSCLC has exceeded three years, demonstrating an unprecedented time for disease progression-free survival .

" Borina® ^® is specially developed to penetrate the blood-brain barrier and inhibit resistance mutations caused by other ALK inhibitors, providing an excellent solution for preventing and delaying disease progression ^{.

In July 2020 , Borrena® ^® was approved to be imported by the Hainan Provincial Food and Drug Administration as a clinically urgently needed drug.

References1.

1 ,NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer.

2 ,R.

3 , Mitsudomi T, Suda K, Tomizawa K, et al.

4.
Gouji Toyokawa, et al.
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev DOI 10.
1007/s10555-015-9592-y 4.
Gouji Toyokawa , et al.
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev DOI 10.
1007/s10555-015-9592-y

Leave a comment here}}

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.